Evolus — Third Quarter 2026 Earnings Summary

Evolus reported third-quarter 2026 global net revenue of $78.0 million, representing a 13% increase year-over-year driven by double-digit growth in toxin revenue and a nearly 40% surge in hyaluronic acid gel sales. The company achieved positive adjusted EBITDA of $1.2 million for the quarter, marking the fourth consecutive quarter of profitability on this metric, while reporting a GAAP operating loss of $8.4 million. Evolus reaffirmed its full-year 2026 net revenue guidance between $330 million and $337 million and updated its non-GAAP operating expense outlook to $210 million to $213 million. Strategic developments include the anticipated FDA approval of Evolysse Sculpt by year-end, a new licensing agreement for Profhilo in the United States, and an option agreement to enter the hair growth market.